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Brain haemosiderin in older people: pathological evidence for an ischaemic origin of magnetic
resonance imaging (MRI) microbleeds
Introduction: Magnetic resonance imaging (MRI) cerebral
microbleeds (CMB) arise from ferromagnetic haemosiderin
iron assumed to derive from extravasation of erythrocytes.
Light microscopy of ageing brain frequently reveals foci of
haemosiderin from single crystalloids to larger, predomi-
nantly perivascular, aggregates. The pathological and
radiological relationship between these findings is not
resolved. Methods: Haemosiderin deposition and vascular
pathology in the putamen were quantified in 200
brains donated to the population-representative Medical
Research Council Cognitive Function and Ageing Study.
Molecular markers of gliosis and tissue integrity were
assessed by immunohistochemistry in brains with
highest (n = 20) and lowest (n = 20) levels of putamen
haemosiderin. The association between haemosiderin
counts and degenerative and vascular brain pathology,
clinical data, and the haemochromatosis (HFE) gene H63D
genotype were analysed. The frequency of MRI CMB in
10 cases with highest and lowest burden of putamen
haemosiderin, was compared using post mortem 3T MRI.
Results: Greater putamen haemosiderin was significantly
associated with putaminal indices of small vessel ischae-
mia (microinfarcts, P < 0.05; arteriolosclerosis, P < 0.05;
perivascular attenuation, P < 0.001) and with lacunes in
any brain region (P < 0.023) but not large vessel disease, or
whole brain measures of neurodegenerative pathology.
Higher levels of putamen haemosiderin correlated with
more CMB (P < 0.003). Conclusions: The MRI-CMB
concept should take account of brain iron homeostasis,
and small vessel ischaemic change in later life, rather than
only as a marker for minor episodes of cerebrovascular
extravasation. These data are of clinical relevance, sug-
gesting that basal ganglia MRI microbleeds may be a
surrogate for ischaemic small vessel disease rather than
exclusively a haemorrhagic diathesis.
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Introduction
Cerebral microbleeds (CMB) appear as small (generally
<5-mm diameter), magnetic resonance imaging (MRI)
signal voids best demonstrated in susceptibility-weighted
and gradient echo density scanning sequences. They are
often assumed to reflect microscopic accumulation of
haemosiderin deposits [1,2]. MRI investigations have
indicated that CMB are prevalent in approximately 5–6%
of the normal population. The prevalence increases in
normal ageing where the majority of CMB occur in deep
brain structures, including the putamen [3,4], and in
patients with hypertension, cerebral ischaemia, intracer-
ebral haemorrhage and stroke [5]. An assumption appears
to have arisen, on the basis that the CMB imaging artefact
is caused by paramagnetic properties of haemosiderin
iron, that they arise from processing of extravasated eryth-
rocyte haemoglobin. Combined radiological and histologi-
cal study in post mortem tissue has demonstrated a strong
correlation between microhaemorrhages and MRI CMB in
the context of cerebral amyloid angiopathy (CAA) [6]. The
histopathology of CAA is frequently associated with evi-
dence of microhaemorrhages and the clinical manifesta-
tions include lobar haemorrhages [7]. In circumstances
other than CAA it has been suggested that age-related
changes in the structure of the blood–brain barrier may
result in opening of endothelial junctions thereby allow-
ing egress of red blood cells, resulting in CMB [3,8,9].
However CMB are also well described in the context of
CADASIL, a brain disorder in which characteristic vascu-
lar sclerosis is not associated with pathological evidence
of acute microhaemorrhage and in which clinical intrac-
erebral haemorrhage is very rare [10,11]. Taken with
the association of CMB with cerebral infarction, such
findings raise the possibility that haemosiderin deposition
in the ageing brain may accumulate from sources other
than extravasated erythrocytes. For the purposes of this
report the term CMB will be exclusively used in the context
of the MR paramagnetic artefact. In contrast the histologi-
cal appearances are described as focal haemosiderin
throughout.
Uptake of iron into the brain is unidirectional, complex,
and facilitated by receptor-mediated endocytosis of iron
bound to transferrin [12]. Iron accumulation with age in
post mitotic tissues, especially the brain, is well docu-
mented and thought to arise from the absence of a func-
tional export pathway [13,14]. Oligodendroglia are the
major reservoir of brain iron storage within ferritin, and
iron content is highest in basal ganglia [13]. The term
ferritin refers to fully assembled iron-containing shells.
The apoprotein units that comprise the shell are composed
of a mixture of ferritin light and ferritin heavy derived
from two different genes. In the present study we have
sought evidence to support an alternative hypothesis for
the origin of haemosiderin foci (and by implication the
source of MRI CMB) based on increasing saturation of
iron storage in older brains as a consequence of unidirec-
tional iron uptake. An important consideration is the
nature and origin of haemosiderin. It does not represent a
specific molecular intermediate of haemoglobin degrada-
tion. Rather it is formed within secondary lysosomes as a
complex of ferritin, iron and proteins (including mem-
brane proteins) produced in any circumstances of iron
overload of macrophages and other cell types [15].
Haemosiderin formation is most marked in pathological
disorders associated with iron overload rather than as a
biomarker of previous episodes of bleeding [16]. When
ischaemia due to small vessel disease (SVD) damages brain
tissue, the release of stored iron from oligodendroglia and
other cells, and of the iron incorporated into haem-
containing proteins, may exceed the ability of the sur-
rounding tissue to process it into new ferritin/iron stores.
A local excess of iron could therefore be processed by
macrophages to haemosiderin and transported to a
perivascular location to assist macrophage-mediated
clearance. This hypothesis can be addressed in part
through certain predictions:
• Focal haemosiderin deposition will be significantly asso-
ciated with local indices of ischaemic SVD in compari-
son with large vessel disease and vascular pathology in
other brain regions.
• Focal haemosiderin deposition will be more prominent
in people whose brain is predisposed to increased iron
uptake for example associated with pathogenic HFE
gene mutations.
• People with a higher burden of focal haemosiderin
deposits in one brain region will have more CMB in other
brain areas based on the usual widespread impact of
SVD.
The aim of the present study was to address these
predictions histologically by quantifying putamen
haemosiderin deposition in an unselected, population-
based cohort of elderly individuals from the Medical
Research Council Cognitive Function and Ageing Study
(MRC CFAS) [17]. We assessed the relationship between
haemosiderin deposition and a variety of measures,
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including local vascular pathology, global brain pathology
scores, dementia status, clinical risk factors for vascular
disease, and the HFE H63D genotype. The relationship
between histologically identified haemosiderin and CMB
MRI voids was determined in a subgroup of cases. Such
data can only address the specific hypothesis that brain
haemosiderin deposits are related to the severity of local
vascular pathology. They do not address the underlying
hypothesis that the source of this haemosiderin is pre-
dominantly derived from oligodendrocyte ferritin and
glioneuronal haem-containing proteins rather than from
erythrocyte breakdown.
Materials and methods
Human central nervous system (CNS) material
Human CNS tissue from 200 brain donors was obtained
from MRC CFAS autopsy cohort. CFAS is a longitudinal,
prospective population-representative study in which
brain donor recruitment was solely based on age (over 65
years) [18] and was unrelated to dementia or other clini-
cal data. The donated brains were pathologically assessed
by neuropathologists following the Consortium to Estab-
lish a Registry of Alzheimer’s Disease (CERAD) protocol
[19] and Braak staging [20] in addition to assessments of
vascular pathology, including arteriosclerosis, atheroma,
SVD, microinfarction, lacunes and parenchymal integrity.
All cases were previously screened for the HFE H63D poly-
morphism [21]. Multi-Centre Research Ethical Committee
approval was given for all procedures.
Focal haemosiderin deposition, local vascular
pathology, global vascular and degenerative
pathology, clinical data
Formalin-fixed blocks, processed and embedded in
paraffin wax, were sectioned at 6 μm and stained with
haematoxylin and eosin (H&E). Histological evaluation of
focal haemosiderin deposits were assessed in the putamen
at coronal levels corresponding to levels 11–14 of the
Newcastle Brain Map (https://nbtr.ncl.ac.uk). In a sub-
group of cases the presence of haemosiderin was con-
firmed using Perls’ Prussian blue stain (Figure 1d). The
total number of discrete perivascular and/or neuropil
deposits of haemosiderin (as single profiles or clusters of
profiles) in the putamen was counted blind to any clinical
or pathological data (Figure 1a,b). The area of the
putamen in each section was measured using a point-
counting approach: A clear acetate marked with points in
a 2-mm grid pattern was placed over the microscope slide
with random orientation and position. The number of
points falling over the putamen was counted. This process
was repeated five times and the mean of these counts cal-
culated and multiplied by 0.04 to give the cross-sectional
area in cm2. The density of haemosiderin deposits was
expressed for statistical analysis as number per unit area of
tissue.
In the same H&E-stained sections the presence of vas-
cular pathology and ischaemic parenchymal damage
was assessed and recorded. These markers included the
presence of: atheroma of larger perforating arteries;
significant arterial and arteriolar sclerosis; microinfarcts;
perivascular (Figure 1c) or more widespread attenuation
and rarefaction of the parenchyma (often associated with
neuronal loss and astrogliosis), arteriolar microaneurysm
formation.
Other pathological data on the donors were obtained
from the archives of the MRC CFAS (http://www.cfas.
ac.uk). These included CERAD and Braak scores for
Alzheimer plaques and tangles and evaluations of cerebro-
vascular disease, especially cerebral infarcts, lacunes and
SVD. SVD in CFAS is defined as the presence of one or more
of the following: moderate or severe arteriosclerosis and/or
arteriolosclerosis, microinfarcts, severe white matter
attenuation [18,22]. CFAS collects information from study
respondents and informants including the presence of
dementia, stroke, diabetes and heart disease [23].
Immunohistochemistry and quantification
Deparaffinized 6-μm sections of the putamen were incu-
bated with 3% H2O2 in methanol for 20 min to block
endogenous peroxidase activity. Sections were micro-
waved in trisodium citrate solution (pH 6.5) for antigen
retrieval and blocked with 1.5% normal sera for 30 min
before incubation with the primary antibody for 1h at
room temperature [glial fibrillary acidic protein: GFAP
(1:500, Dako, Ely, UK); CD68 (1:100, Dako); CD163
(1:100, Serotec, Kidlington, UK); fibrinogen (1:400, Alere
Ltd, Stockport, UK); ferritin (1:1000, Sigma, Poole, UK)].
The avidin-biotin horseradish peroxidase (ABC-HRP)
complex method was used (Vectastain Elite kit, Vector
Laboratories, Peterborough, UK), with diaminobenzidine
(DAB) as the substrate. Five random regions within the
area of interest were selected (×20 magnification; Cell∧R,
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Olympus, Southend-on-Sea, UK), and the percentage area
immunoreactivity of the image analysed using analysis∧D
software (Olympus Biosystems, Planegg, Germany) fol-
lowing delineation and exclusion of vascular profiles and
voids in the sections.
MRI scanning of the frontal lobe
Magnetic resonance imaging analysis to detect CMB pro-
files were investigated in 12 cases. These included six cases
with the highest frequencies of focal haemosiderin depos-
its, as assessed by histological examination, compared with
six with the lowest burden of focal haemosiderin. For each
case five formalin-fixed coronal slices of the frontal lobe
(5–8 mm thick) were submerged in fomblin oil (Solvay
Solexis, Spinetta Marengo, Italy) in a custom built Perspex
chamber (Figure 2a; Royal Hallamshire Hospital, Engi-
neering Workshop). MRI (Philips, Eindhoven, the Nether-
lands) was performed at 3.0Tesla using a susceptibility-
weighted protocol optimized forpostmortembrain imaging.
The parameters for the susceptibility weighted sequence
were: repetition time 29 ms; echo time 15 ms; flip angle
15°; voxel size 0.45 × 0.45 × 1 mm (slice thickness
1 mm); number of excitations 2; acceleration factor 1.2.
For conventional gradient echo T2 weighted sequences the
parameters were: repetition time of 500 ms; echo time
16 ms; flip angle 16°; voxel size 0.45 × 0.44 × 2.0 mm
(slice thickness 2 mm); number of excitations 3. The
a b
c d
Figure 1. (a, b) Haemosiderin deposits. Grouped clusters of several profiles (a; arrow) were counted as a single focus. Foci of haemosiderin
were identified in both periarterial (and arteriolar) and pericapillary locations (b; arrows). (c) Perivascular attenuation was interpreted as
parenchymal ‘loosening’ and vacuolation around arterioles and small arteries, or within parenchyma, whether or not associated with
gliosis. (d) Perivascular stainable-iron deposition was confirmed using Perl’s staining. (a,b,c haematoxylin and eosin; d Perl’s stain: a,c ×40
obj; b ×10 obj; d ×20 obj.)
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number of CMB in the MRI images was scored by consen-
sus blinded to any clinical or neuropathological informa-
tion (B.M.J./N.H.). CMB were defined as foci of blooming
artefact up to 5 mm in diameter that may represent
microhaemorrhages taking care to count away from sulci
to avoid air/fluid interface artefact. The number of CMB
present in each brain scan was counted and adjusted for
the size of the tissue slab. This was achieved by dividing the
CMB count in each slice by the surface area expressed as the
number of pixels in standardized MRI images. As all
brain slices were scanned using the same apparatus
and scanner the only variation in image size was due to
brain size.
Statistical analysis
Inter-rater reliability for haemosiderin counting was
assessed using Spearman Rank correlation, with addi-
tional analysis of inter-observer bias (paired t-test) and
reproducibility (mean and 95% confidence interval of
inter-observer difference).The strength of association
of focal putaminal haemosiderin deposition and global
pathology, local neuropathology, clinical information and
molecular markers and the HFE H63D genotype was
assessed using either the Wilcoxon Rank Sum Test or the K
Sample Median Test. Analyses were performed using
STATA version 12.0.
Results
Haemosiderin deposition in the putamen in
ageing brains
Putaminal haemosiderin deposition, evident as crystalloid
profiles varying from dark brown to a lighter reddish-
brown granular material, occurred in 99% of the ageing
population aged 65 and older (198/200 cases), as
assessed in H&E-stained sections (Figure 1a,b). There was
significant association between haemosiderin deposition
identified in H&E sections and by the Perls’ Prussian
blue method (Figure 1d; P < 0.001; Wilcoxon Rank Sum
test). A significantly higher number of haemosiderin
deposits were detected in periarterial/periarteriolar
regions (mean 7.68 ± 0.952) compared with parenchy-
mal (pericapillary) locations (2.79 ± 0.55) (P < 0.001)
(Figure 2b). There was good agreement between the
counts of the two observers (P.G.I., B.M.J.: Spearman:
r = 0.89, P = < 0.001) and there was no evidence of inter-
observer bias (t = 1.83, P > 0.08; mean inter-observer dif-
ference = 20.4, 95% confidence interval −2.8 to 43.61).
Figure 3 shows the distribution of focal haemosiderin
counts within the cohort. While two-thirds of the cohort
have a density below two deposits per cm2 there is a large
tail of cases with more frequent haemosiderin deposition.
a b
Figure 2. (a) Perspex chamber loaded with formalin fixed frontal lobe brain slices used to present tissue for magnetic resonance imaging
(MRI). (b) Susceptibility weighted 3T MRI scan image of a representative slab of brain tissue showing two signal voids (arrows) with the
characteristics of microbleeds.
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Relationship of haemosiderin to global
neuropathology and local vascular pathology
There was no evidence that haemosiderin deposition in
the putamen was related to severity of whole brain meas-
ures of neuropathology, including Braak stage (P = 0.88),
CERAD senile plaque severity (P = 0.53) or presence
of synucleinopathy (P = 0.83), amyloid angiopathy
(P = 0.36) and SVD (P = 0.36). Comparison with whole
brain assessment of presence of lacunes showed a positive
association with severity of haemosiderin deposits
(P = 0.023).
There were significant associations with indices of
local vascular pathology, including both pathology of
small vessels and ischaemic parenchymal lesions, in the
putamen. The intensity of haemosiderin deposition
was higher in people with putaminal microinfarcts
(P = 0.015), arteriolosclerosis (P = 0.022) and changes
of perivascular attenuation (P < 0.001), but no associa-
tion was found with atheroma (P = 0.13), arteriosclero-
sis (P = 0.17) or microaneurysm (P = 0.51), as shown in
Table 1 and Figure 4.
Relationship of focal haemosiderin to molecular
markers of pathology, gliosis and tissue integrity
in the putamen
CD68+ microglia were predominantly of a highly
branched morphology and were evenly distributed
throughout the putamen and did not appear associated
with haemosiderin deposition (P = 0.69). A distinct subset
of CD163+ perivascular macrophages was detected in
some cases and were significantly correlated with
haemosiderin deposition (P = 0.005). The density of GFAP
immunoreactive astrocytes (P = 0.261), myelin density
(determined by immunostaining for MBP; P = 0.35) and
ferritin immunoreactive cells (P = 0.79), predominantly
oligodendrocytes and astrocytes, were not related to
haemosiderin deposition.
Relationship to clinical information
and HFE genotype
Analysis of the extent of focal haemosiderin deposition
was statistically analysed in relation to data related to
Figure 3. Bar chart showing distribution of haemosiderin density in the putamen across the cohort.
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brain weight, age and self-reported clinical parameters rel-
evant to cardiovascular and cerebrovascular risk factors.
Higher haemosiderin deposition was significantly associ-
ated with increasing age (Spearman’s Rho = 0.22,
P = 0.0016) and lower brain weight (P < 0.001), but was
not associated with brain atrophy (P = 0.25), dementia
(P = 0.34), diabetes (P = 0.90), gender (P = 0.68), myo-
cardial infarction (P = 0.44), stroke (P = 0.45) and sys-
temic hypertension (P = 0.49).
Previous HFE genotyping of the H63 locus in these indi-
viduals showed that 66.1% were homozygous for the wild-
type allele (H/H), 30.4% were heterozygous (H/D) and
3.6% homozygous (D/D) [19]. Haemosiderin burden was
not significantly higher in HFE H63D carriers compared
with noncarriers (P < 0.053), although the relationship
came close to conventional statistical significance.
However this component of the study has rather limited
power due to the small sample size for a genetic associa-
tion analysis and needs to be repeated in a larger cohort.
Correlation of pathological evidence of
haemosiderin in the putamen with MRI evidence
for microbleeds in other brain areas
Formalin fixed frontal lobe brain tissue coronal slices
underwent MRI analysis at 3.0T in a custom built Perspex
chamber (Figure 2a), and showed profiles corresponding
to typical microbleed signal voids (Figure 2b). The MRI
method was optimized to ensure that the signal voids dem-
onstrated most likely correspond to CMB as described
in clinical imaging of living patients [2]. The use of an
immersion oil was found to minimize artefacts associated
with air and water interfaces and edge artefacts. Compari-
son of the frequency of CMB profiles in six cases selected
with high frequency of putamen focal haemosiderin
deposition and six cases selected with low deposition
showed that more microbleeds (predominantly in a frontal
white matter distribution) is shown in Table 2. The area
of CMB in MRI images from cases with high putamen
haemosiderin counts was significantly increased
(P = 0.003).
Discussion
It is widely assumed that MRI CMB reflect extravasation of
red blood cells from cerebral blood vessels, resulting in
pericyte erythrophagocytosis, haemoglobin degradation
and haemosiderin deposition [1–3,5]. In this population-
based neuropathology study we report the prevalence of
putamen focal haemosiderin deposition assessed by light
microscopy and show that it is significantly associated
with indices of SVD, age and low brain weight. The HFE
Table 1. Association between putaminal haemosiderin deposition, brain pathology scores, local vascular pathology measures and
cerebrovascular risk factor clinical data
Absent Present
PMedian IQR Median IQR
Global pathology CAA – – – – 0.77
Braak stage – – – – 0.88
Senile plaque score – – – – 0.21
Synucleinopathy – – – – 0.83
Small vessel disease 1.6 0.8–2.6 1.7 0.9–3.0 0.36
Lacunes 1.4 0.7–2.6 2.1 0.9–4.6 0.02
Local pathology Arterial sclerosis 1.6 0.8–2.8 1.5 0.5–2.6 0.17
Arteriolosclerosis 1.3 0.9–3.3 1.7 0.6–2.2 0.02
Atheroma 0.5 0.9–4.6 1.8 0.6–2.7 0.13
Microinfarcts 1.3 0.9–3.3 1.9 0.6–2.5 0.01
FPVA 1.1 0.9–3.2 1.8 0.4–1.8 0.0003
Clinical risk factors Age – – – – 0.01
Gender – – – – 0.41
Diabetes – – – – 0.90
Stroke – – – – 0.45
Heart disease – – – – 0.44
Dementia – – – – 0.34
IQR, interquartile range; CAA, cerebral amyloid angiopathy; FPVA, focal perivascular attenuation.
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e f
Figure 4. Box and whisker plots showing relationship between the density of haemosiderin deposition and both local (a,c–f) and global (b)
measures of vascular pathology.
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H63D genotype was not significantly associated with
severity of haemosiderin deposits in this cohort. We
propose that accumulation of focal haemosiderin deposits
in older peoples brains in part reflects the inability of the
ageing brain to store ferritin iron released from ischemic
damage to oligodendrocytes and other cells because of a
reduced overall population of remaining healthy brain
cells. Oligodendrocytes are recognized to be vulnerable to
ischaemia during development but there is increasing
evidence of similar vulnerability in adult white matter
diseases [24]
Basal ganglia structures contain the highest concentra-
tion of iron in the brain [25]. Previous histological analy-
sis of the putamen in the ageing population has suggested
that haemosiderin deposition primarily occurs at the
capillary level [3], in contrast we report a significantly
higher number of haemosiderin deposits in periarterial/
periarteriolar regions compared with pericapillary loca-
tions. This difference may reflect the large sample size, and
population-based sampling, of the CFAS cohort investi-
gated in this study, compared with the previous report (33
cases) [3].
Cerebral microbleeds are small MRI signal voids indica-
tive of focal haemosiderin deposition. Several MRI studies
have investigated the prevalence of microbleeds in the
ageing population, and report CMB frequencies rang-
ing from 3% to 38% [4,26–29]. In contrast to these
MRI studies, we report histological detection of focal
haemosiderin deposition in 99% of CFAS cases aged 65
years and over, suggesting that histology is currently a
more sensitive technique for detecting haemosiderin inpost
mortembrain tissue than MRI analysis. MRI parameters for
the detection of CMB vary between these studies and likely
contribute to the wide range of prevalence reported. For
example increasing the magnet strength from 1.5T to 3.0T
has been shown to increase the number of detectable of
CMB [30]. Emerging experience of imaging at higher field
strengths suggest a predictable increase in rate of detec-
tion, and the apparent size of CMB detected [31]. However,
in line with these imaging studies, we report a significant
positive association between haemosiderin deposition and
age [4,26–29]. Furthermore, consistent with MR CMB evi-
dence from the Rotterdam Scan Study [4], but not the Age,
Gene/Environment Susceptibility (AGES) Reykjavik Study
[28] nor the Framingham Study [26], we report no signifi-
cant association between gender and prevalence of focal
haemosiderin deposits. Taken together these data support
the hypothesis that haemosiderin deposits need to accu-
mulate to a sufficient size, or ferromagnetic potential, in
order to become detectable as MRI lesions. We suggest that
there is no pathogenetic or qualitative difference between
histological focal haemosiderin and MRI CMB, simply a
matter of a ‘size’ threshold.
Increased focal haemosiderin deposition in brains from
the CFAS population significantly correlates with indica-
tors of SVD, including microinfarcts, arteriolosclerosis,
lacunes and perivascular attenuation, concordant with
data from population-based MRI analyses [27,29], but not
measures of global neuropathology. In contrast to studies
which suggest that the prevalence of CMB impacts cogni-
tive function in stroke clinic patients [32,33] and a
population-based ageing cohort [34], we report no signifi-
cant correlation between focal haemosiderin deposition
and dementia status. CMB are simultaneously located in a
variety of brain regions, including subcortical white
matter and the basal ganglia, in SVD patients [35,36].
In the current study, cases with the highest levels of
haemosiderin deposition in the putamen also have MRI-
detectable CMB in the frontal lobe, predominantly in the
white matter, suggesting that CMB may reflect widespread
SVD in the ageing brain. MRI-based correlations with
dementia status derived from clinical case-control studies
are not directly comparable to the present population-
based data as they likely select for cases with the high levels
of haemosiderin that may be less frequent at a population
level.
Table 2. Comparison of area of MRI CMB in frontal lobe tissue slices in brains characterized by high (6) and low (6) focal haemosiderin
counts in the putamen
Area of MRI cerebral microbleeds (CMB pixels/total pixels)
Category Total CMB IQR 25th centile 75th centile P
High putamen haemosiderin 0.697 0.356 0.545 0.89
Low putamen haemosiderin 0.28 0.226 0.167 0.391 0.003
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It is generally assumed that the CMB detected by MRI
represent sites of microhaemorrhage which result in
extravasation of erythrocytes and give rise to small foci of
chronic blood products and haemosiderin deposition.
This concept is curious as there is no established litera-
ture about similar minor spontaneous extravasations in
peripheral tissues lying outside the blood–brain barrier.
An evaluation of skin in the leg related to chronic venous
stasis for example found perivascular haemosiderin to be
infrequent and usually associated with local inflamma-
tion [37]. The microbleed literature often refers to an
older study in which the presence of microaneurysms
(of Ross Russell) was related to the presence of small
haemorrhages [38]. However the ‘small’ haemorrhages
described in that paper were detected macroscopically,
not by microscopic examination, as lesions ‘less than
30 mm in diameter’ and they were present in patients
with severe hypertension (defined as diastolic blood pres-
sure > 110 mmHg accompanied by cardiomegaly). This
study group from 1967 is likely to be very different from
the present day elderly medicated population, and the
type of lesion described is likely to be different from the
small foci of haemosiderin detected by microscopy and as
MRI CMB in the modern literature. In contrast to this
idea of an origin from extravasation we propose that
focal haemosiderin deposits may arise from local iron
sources within the brain. Iron stored within ferritin, the
iron storage protein, is predominantly associated with
oligodendrocytes in the CNS [39]. Dysregulation of iron
homeostasis can result in increased oxidative stress
and ultimately neurodegeneration [40], therefore iron
content in the CNS is strictly regulated by a number of
proteins, including HFE [41]. The H63D polymorphism
in the HFE gene is associated with increased iron
uptake and ultimately iron overload [42–46]. In this
study we were unable to demonstrate a significant asso-
ciation between the HFE H63D polymorphism and
greater burden of haemosiderin deposition. Most of the
H63D mutation detected was heterozygous, in which
dysregulated iron uptake is less pronounced, and where
increased iron uptake does not give rise to haemochro-
matosis. The cohort size is also rather small for a genetic
association study. A more definitive test of our hypoth-
esis, given the modest power to test it using these genetic
data, would be to make direct measurements of brain
iron content for comparison with data on CMB and
microscopical focal haemosiderin deposits. There is also
an urgent need for better histopathological studies to
characterize the range and threshold of haemosiderin
pathology that can give rise to an MRI microbleed
artefact.
Haemosiderin deposition in this study was associated
with elevated expression of CD163 immunoreactive
perivascular cells, a haem scavenger receptor expressed by
macrophages [47,48]. The lack of a characterized func-
tional iron export pathway from the brain likely results in
the perivascular accumulation of haemosiderin, some of
which may be mobilizable via macrophage activity. While
our data do not exclude the possibility that this is a
response to extravasated erythrocytes we did not observe
recent perivascular haemorrhage in any of our cases. The
presence of perivascular haemosiderin in CADASIL cases,
in which there is massive arteriolar fibrosis, no evidence of
a clinical propensity for haemorrhage, and very severe
ischaemic white matter degeneration, further supports
the possibility that deposited iron can arise from damaged
parenchyma rather than being vascular in origin. Of
interest the chief neuropsychological correlates associ-
ated with CMB are precisely those now invoked as the core
features of subcortical ischaemic encephalopathy related
to small vessel ischaemia [33,49,50].
It is potentially important to distinguish CMB, and the
pathological correlates of haemosiderin deposition, in
different anatomical loci. CAA is associated with a high
frequency of cortical MRI CMB [1]. Histopathology of
CAA shows microaneurysm formation, inflammation,
small perivascular bleeds and microinfarction [7]. Clini-
cally CAA is undoubtedly a major risk factor for lobar
haemorrhage. We therefore suggest that CMB in a corti-
cal distribution likely do have a role as a biomarker for
risk of clinical haemorrhage due to underlying CAA in
older people at risk of that pathology. Our data, in con-
trast, are consistent with the hypothesis that white
matter and basal ganglia focal haemosiderin/CMB depos-
its are frequently ischaemic in origin and have different
biomarker implications. In terms of the predictions
addressed in this study we have demonstrated that focal
haemosiderin deposition is significantly associated with,
predominantly local, indices of ischaemic SVD but not
to neurodegeneration, large vessel disease and vascular
pathology in other brain regions, and that people with a
higher burden of focal haemosiderin deposits (and small
vessel ischaemia) in the putamen have more CMB in
other brain areas. Further clinical and pathological
studies are needed to address this ischaemic hypothesis
for the origin of CMB.
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